AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to Evaluate Ficlatuzumab and Erbitux (cetuximab) for Recurrent or Metastatic HNSCC
Shots:
- The companies collaborated to evaluate ficlatuzumab + Erbitux in registrations study in patients with recurrent or metastatic HNSCC. The study is expected to initiate in H1’23
- Merck KGaA will provide cetuximab clinical drug supply in all countries outside of the US & Canada for AVEO’s registrational study to evaluate ficlatuzumab + cetuximab for HPV negative R/M HNSCC. AVEO will be the study sponsor & will be responsible for costs associated with trial execution
- The company is planning to initiate the manufacturing of ficlatuzumab clinical supply in Q2'22. Ficlatuzumab is being evaluated in HNSCC & metastatic PDAC & has received FTD from the US FDA for recurrent or metastatic HNSCC
Ref: Globe Newswire | Image: Merck KGaA
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com